Cosar Pharmaceutical Company (شرکت داروسازی کوثر) — complete B2B supplier profile on TraidB

About Cosar Pharmaceutical Company (شرکت داروسازی کوثر)

Cosar Pharmaceutical Company was established in 1973 under the name Chemico Pharmaceutical Company. Initially, it produced oral antibiotics under license from Beecham Pharmaceuticals of England. Over time, with the establishment of new production lines for non-antibiotic solid oral drugs, other generic products, supplements, and natural products in dosage forms such as tablets, capsules, sachets, syrups, and bulk powders were added to the company's product portfolio. In 2021, a production line for solid oral drugs with exposure level 3 and 3+ was added for the production of central nervous system drugs and some new drugs subject to these requirements. The company's first biosimilar drug is expected to enter the market in 2023.

Vision

Improving people's lives by providing innovative drugs, generics, and supplements. We are committed to becoming one of the top knowledge-based pharmaceutical companies through extensive research and providing innovative solutions for today's and tomorrow's needs of society.

Services (4)

  • SUS.IRAM
  • TAB.HEP
  • Indawel 2.5 mg
  • Indawel 1.5 mg

Cosar Pharmaceutical Company (شرکت داروسازی کوثر)

Manufacturer
Request RFQ Send Message
83
Products
60
Processes
4
Services

See the full company profile

Sign in to view Cosar Pharmaceutical Company (شرکت داروسازی کوثر)'s products, services, certificates and direct contact details.

Products Contact details Certificates Services

About Us

Cosar Pharmaceutical Company was established in 1973 under the name Chemico Pharmaceutical Company. Initially, it produced oral antibiotics under license from Beecham Pharmaceuticals of England. Over time, with the establishment of new production lines for non-antibiotic solid oral drugs, other generic products, supplements, and natural products in dosage forms such as tablets, capsules, sachets, syrups, and bulk powders were added to the company's product portfolio. In 2021, a production line for solid oral drugs with exposure level 3 and 3+ was added for the production of central nervous system drugs and some new drugs subject to these requirements. The company's first biosimilar drug is expected to enter the market in 2023.

Our Vision

Improving people's lives by providing innovative drugs, generics, and supplements. We are committed to becoming one of the top knowledge-based pharmaceutical companies through extensive research and providing innovative solutions for today's and tomorrow's needs of society.

Login to View Processes

This information is available only to registered users.

Login

Login to View Services

This information is available only to registered users. Please login or create an account to view full details.